Results for this period
Interim period (second quarter)1 April 2026 to 30 September 2026Non-consolidated (individual)Japanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ thousand).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
There was no business revenue, as there was no milestone income or other such revenue. Business expenses were recorded due to the increase in the number of medical institutions and cases in clinical trials for the development pipeline, as well as the manufacture of drug substances and drug products for the next trial.
Not applicable.
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Non-consolidated (individual) |
| Period Covered | 1 April 2026 to 30 September 2026 |
| Operating profit | ¥-795 million |
| Ordinary income | ¥-801 million |
| Profit attributable to owners of the parent | ¥-802 million |
| Net income per share | -¥53.88 |
| Equity ratio | End of the current fiscal period 2.6 / End of previous period 12.6 |
| Total assets | ¥344 million |
| Net assets | ¥10 million |
| Cash flows from operating activities | ¥-659,036 thousand |
| Cash flows from financing activities | ¥772,355 thousand |
| Cash and cash equivalents at end of period | ¥257,461 thousand |
| Full-year earnings forecast | Net Sales Not disclosed / Operating profit ¥-1,330 million / Ordinary income ¥-1,340 million / Net income ¥-1,350 million |
| Annual Dividend Forecast | 0 yen → 0 yen（0.0%） |
| Depreciation and amortization | ¥687 thousand |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards None / Other changes None / Change in accounting estimate None / Restatement None |
| Material subsequent events | During the period from 1 October 2026 to 12 November 2026, the 12th Series of Stock Acquisition Rights were exercised, resulting in the issuance of 1,620,000 common shares and an increase of ¥60,393 thousand each in stated capital and the capital reserve. |
| Availability of Supplementary Financial Results Materials | Available |
| Availability of Financial Results Briefing | Available (for institutional investors and analysts) |
| Issued Shares at Period-End | 19,285,000 shares |
| Treasury Shares at Period-End | 198 shares |
| Factors Behind Changes in Business Performance | There was no business revenue, as there was no milestone income or other such revenue. Business expenses were recorded due to the increase in the number of medical institutions and cases in clinical trials for the development pipeline, as well as the manufacture of drug substances and drug products for the next trial. |
Items this document does not state (13)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.There was no business revenue, as there was no milestone income or other such revenue. Business expenses were recorded as the number of medical institutions and cases increased in clinical trials for the development pipeline, and the company proceeded with the manufacture of drug substances and drug products for the next trial.